Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses
Nutrition, Metabolism and Cardiovascular Diseases · 2026
DOI: 10.1016/j.numecd.2026.104815 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026. Verfasst von Wei-Hao Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Carotid Artery Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation, Jiangsu Province Natural Science Foundation.
Abstract (Originalsprache)
BACKGROUND AND AIM: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major contributor to chronic liver disease worldwide, yet the risk factors for carotid plaque in MASLD patients remain unclear. This study aimed to identify these risk factors. METHODS AND RESULTS: We performed a retrospective cross-sectional analysis of 5372 participants, of whom 2673 met the 2023 MASLD criteria. The MASLD cohort was randomly divided into a training set (70%) and a validation set (30%) to develop a predictive model for carotid atherosclerosis risk. The model's performance and goodness-of-fit were assessed via internal and external validation. Additionally, Mendelian randomization (MR) analysis was performed to investigate the causal relationships between identified risk factors and carotid atherosclerosis. MASLD was significantly associated with carotid plaque formation (P < 0.001). Multivariate analysis identified age, sex, fasting plasma glucose (FPG), and systolic blood pressure (SBP) as independent risk factors, which were used to construct a predictive model (AUC = 0.801, 95% CI: 0.782-0.821). Subgroup analysis indicated that MASLD patients with glucose metabolism abnormalities had a higher plaque risk. MR analysis provided genetic evidence suggesting that genetically proxied SBP (P = 0.018) and FPG (P = 0.004) were associated with carotid atherosclerosis. CONCLUSIONS: A novel predictive model (XY-CPRM) can identify the risk of carotid plaque in the MASLD population. Intensive management of blood glucose and blood pressure is a critical strategy to mitigate cardiovascular risk in MASLD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Xuzhou Medical University, Xuzhou, China.
- Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Infectious Disease, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Infectious Disease, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Electronic address: jifang800410@foxmail.com.
Förderung
- Wu Jieping Medical Foundation
- Jiangsu Province Natural Science Foundation
Zitieren
APA
Peng, W. H., Zhang, J., Ruan, Y. H., Li, Y., Liu, Y., Dai, M. J., Jin, J. K., Yan, X. B., & Ji, F. (2026). Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2026.104815
Vancouver
Peng WH, Zhang J, Ruan YH, Li Y, Liu Y, Dai MJ, et al. Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses. Nutrition, Metabolism and Cardiovascular Diseases. 2026. doi:10.1016/j.numecd.2026.104815
BibTeX
@article{Peng2026,
author = {Peng, Wei-Hao and Zhang, Jing and Ruan, Yu-Hua and Li, Yan and Liu, Ye and Dai, Ming-Jia and Jin, Jing-Kun and Yan, Xue-Bin and Ji, Fang},
title = {Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.numecd.2026.104815}
}
EUVIMED